Australian biotech market watch 02/10/09
Friday, 02 October, 2009
The All Ordinaries has followed the Dow Jones and other international indices by dropping nearly 2% in today's trading on the back of fears of continued economic strife in the United States. The health index managed to keep the slide to a minimum, shedding only 0.7%.
At the forefront of the losses was Biota Holdings (ASX:BTA), which receives royalties for the anti-viral drug, Relenza, which dropped 2.8% to $2.77.
Ramsay Health Care (ASX:RHC) also lost 2% of its value, down to $10.86, bringing it back to its Monday start after peaking at $11.10 mid-week.
Medical implant company, Cochlear (ASX:COH) saw a $1.15 dip to $66.42, and CSL (ASX:CSL) slipped 22c to $33.22.
It wasn't all bad news though. Blackmores (ASX:BKL) nudged upwards half a per cent to $20.23, after having a shaky start this morning.
Photoprotective drug company, Clinuvel (ASX:CUV) also saw a late jump of over 10% to $0.38, putting its stock at a four month high.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
